Plain-English translation of ·
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new medication called combined with two existing blood cancer drugs ( and ) to see if it helps people with newly diagnosed acute myeloid leukemia live longer and have better outcomes. The study will involve about 660 adults worldwide who have been newly diagnosed with this serious blood cancer but are not healthy enough for intensive chemotherapy. The medication is given as an infusion into a vein, while the other treatments are either tablets by mouth or injections.
Many people with acute myeloid leukemia are too frail or have other health conditions that make standard intensive chemotherapy too dangerous. This trial is testing whether adding this new medication to gentler existing treatments can provide better results for these vulnerable patients.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either the new medication plus the two standard drugs, or the standard drugs alone (or a placebo plus the standard drugs in the later phase of the study). You will visit a hospital or clinic regularly for blood tests, medical exams, and to receive your treatments—the new medication as an infusion, and the other medications as either pills, injections, or infusions depending on where you are enrolled. The entire study lasts about 71 months (nearly 6 years), though your individual commitment may be shorter depending on how your cancer responds and your health.
AI-generated summary from trial data · Aug 2, 2026 · Not medical advice
United States
Israel